TD Issues Pessimistic Forecast for Aurora Cannabis (TSE:ACB) Stock Price

Aurora Cannabis (TSE:ACB) had its price objective reduced by stock analysts at TD to C$8.00 in a research report issued on Friday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. TD’s target price suggests a potential upside of 88.24% from the stock’s previous close.

Aurora Cannabis Trading Down 0.7%

Aurora Cannabis stock traded down C$0.03 during mid-day trading on Friday, hitting C$4.25. The company’s stock had a trading volume of 371,398 shares, compared to its average volume of 412,147. The firm has a market capitalization of C$251.29 million, a PE ratio of -2.83 and a beta of 0.17. Aurora Cannabis has a 1 year low of C$3.77 and a 1 year high of C$9.33. The company has a current ratio of 3.06, a quick ratio of 2.48 and a debt-to-equity ratio of 25.02. The stock’s fifty day moving average is C$4.77 and its two-hundred day moving average is C$5.31.

Aurora Cannabis (TSE:ACB) last issued its quarterly earnings data on Thursday, June 11th. The company reported C($0.99) earnings per share for the quarter. The business had revenue of C$38.01 million during the quarter. Aurora Cannabis had a negative return on equity of 1.15% and a negative net margin of 1.69%. On average, analysts anticipate that Aurora Cannabis will post -0.22 EPS for the current year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.